Karen Daily Weinstein, DO
Hematology & Oncology · Gainesville, FLNPI 1770547648
Payments from drug & device makers
Across 69 payments — averaging $11,533 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$435K
- Merck$189K
- Astrazeneca UK Limited$143K
- F. Hoffmann-la Roche AG$19K
- AstraZeneca$8K
- Gilead$652
- plus $1K from 3 others
Across 2 payments — averaging $2419.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5K
What the payments were for
- Consulting fees$9,20520%
- Speaking & faculty fees$24,78053%
- Grants$3501%
- Travel & lodging$11,37524%
- Food & beverage$7422%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 17 | $434,884 |
| Merck | 39 | $188,954 |
| Astrazeneca UK Limited | 1 | $142,884 |
| F. Hoffmann-la Roche AG | 1 | $19,110 |
| AstraZeneca | 4 | $8,290 |
| Gilead | 3 | $652 |
| Daiichi Sankyo Inc. | 1 | $550 |
| Athenex Pharmaceutical Division, LLC | 2 | $350 |
| Hologic Sales And Service, LLC | 1 | $127 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$795,801 in reported general payments places this provider in the 80th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 45 | $643,188 |
| IbrancePalbociclib | 23 | $354,147 |
| Letrozole | 570 | $13,333 |
| Exemestane | 61 | $10,157 |
| Tamoxifen Citrate | 53 | $2,226 |
| Anastrozole | 97 | $1,443 |
| Prochlorperazine Maleate | 47 | $1,292 |
| Ibandronate Sodium | 31 | $1,250 |
| Ondansetron Hcl | 49 | $1,067 |
| Olanzapine | 47 | $804 |
| Raloxifene Hcl | 17 | $518 |
| Dexamethasone | 27 | $498 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $246 |
| Duloxetine Hcl | 15 | $220 |
| Gabapentin | 12 | $212 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Gainesville
- Thomas GeorgeGainesville$10.3M
- Carl LandgrenMiami$47.8M
- Julio ChavezTampa$16.4M
- Steven AttiaJacksonville$13.9M
- Santosh NairOrange City$13.5M
- Frederick LockeTampa$12.8M
- Tarek MekhailOrlando$11.2M
- Carlos AlemanyOrlando$10.9M
- Sikander AilawadhiJacksonville$9.8M
- Richard KimTampa$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.